By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).